Lipid-Nanoparticle Based Genomic Medicines Market Size is valued at USD 17.47 Bn in 2023 and is predicted to reach USD 32.49 Bn by the year 2031 at a 8.20% CAGR during the forecast period for 2024-2031.
LNP-based genetic medicines are leading the way in personalized and precision medicine, providing hopeful new therapy possibilities for a diverse array of disorders. Their development and therapeutic application are subjects of ongoing research, having the potential to completely transform the approach to treating genetic and infectious disorders.
Ongoing breakthroughs in nanotechnology, including lipid-based nanoparticles, are driving the development of precise and efficient delivery techniques for genetic therapies, enhancing the effectiveness of these medications. Another driving force behind the adoption of genomic pharmaceuticals, specifically mRNA-based treatments, is their potential to treat a variety of ailments, including genetic disorders, cancer, and infectious diseases. This necessitates the development of delivery mechanisms for lipid nanoparticles. The use of cancer apps serves as an additional incentive.
In this changing landscape, research, strategic alliances, and regulatory advances emphasize lipid-nanoparticle-based genetic medicines as transformative treatments in the age of personalised healthcare. Recent technology platforms include lipid nanoparticles (LNPs). With LNP delivery technologies, over two billion people have received COVID-19 mRNA immunizations or boosters.
Competitive Landscape
Some Major Key Players In The Lipid-Nanoparticle Based Genomic Medicines Market:
- Moderna Inc.
- Pfizer Inc.
- BioNTech SE
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- CureVac N.V.
- Lipocalyx
- Acuitas Therapeutics
- Precision NanoSystems Inc.
- IONTAS Limited
- Genevant Sciences
- Roche Holding AG
- Alnylam Pharmaceuticals Inc.
- SiO2 Materials Science
- Ethris GmbH
- BIOVECTRA
- Avanti Polar Lipids, Inc. (Croda International Plc.),
- Recipharm AB
- eTheRNA
- ST Pharm Co Ltd,
- Other Prominent Players
Market Segmentation:
The Lipid-Nanoparticle Genomic Medicines Market can be segmented based on Type, Application, Therapeutic Payload and End-User. By Type, the market is segmented into Liposome-based Nanoparticles, Micelle-based Nanoparticles, and Lipid-Coated Nanoparticles. The Application segment of the market includes Cancer Treatment, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases, and Others. By Therapeutic Payload, the market is segmented into mRNA-based Therapeutics, siRNA-based Therapeutics, miRNA-based Therapeutics, and Other Genomic Medicines. The End-User segment comprises Hospitals, Biopharmaceutical Companies, Research Institutes, and Others.
Based On Therapeutic Payload, Mrna Therapeutics Are A Growth Contributor In The Lipid-Nanoparticle-Based Genomic Medicines Market.
The research and development efforts undertaken in the mRNA therapeutics domain have evolved substantially over time, owing to their various advantages, including higher biological efficacy, enhanced immunogenicity, and versatile vaccine delivery platforms over other therapeutic modalities. Recent reports highlight the potential benefits of mRNA; for instance, there is no undesirable risk of accidental infection and insertional mutagenesis.
In addition to linear mRNA, circular RNA (circRNA) and self-amplifying RNA (saRNA) vaccine platforms are now being acknowledged by the researchers. mRNA therapeutics and other novel RNA therapeutics like circRNA and saRNA will drive market growth for lipid nanoparticle manufacturing during the forecast period.
By Type-Liposome Based Nanoparticles Segment Witnessed Growth At A Rapid.
A significant number of pharmaceutical as well as biotechnology businesses buy liposome nanoparticles. Throughout the projection period, the category is probably going to show a high CAGR. The main focus of these market players is developing new drugs and therapies. Prominent biotech and pharmaceutical firms are anticipated to create novel nanoparticles that would offer a versatile delivery system for various pharmacological substances, such as biologics, nucleic acids, peptides, and small molecules. By using lipid nanoparticles, these businesses are expected to improve the solubility, stability, and bioavailability of new compounds, leading to the development of more effective medications.
North America Has A Significant Revenue Share In The Lipid-Nanoparticle Genomic Medicines Market Region.
In the region, North America leads the Lipid-Nanoparticle Genomic Medicines Market in terms of revenue share. The broad use of mRNA-based vaccinations and treatments is the main trend in North America. Sufficient funding for biopharmaceutical research fosters innovation, with a particular emphasis on extending the use of lipid-nanoparticle genetic therapies to disorders such as neurodegenerative ones.
The region's leadership in the development of genetic medicine is partly attributed to regulatory backing and partnerships between academics and business. Europe and the Asia-Pacific region place a strong emphasis on sustainable lipid nanoparticle technology. Research on environmentally friendly lipid formulations and resolving environmental issues are trends. Additionally, the region is home to cooperative efforts in precision oncology, with an emphasis on lipid-based drug delivery system improvements and personalised genetic therapy.
Lipid-Nanoparticle Based Genomic Medicines Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 17.47 Bn |
|
Revenue Forecast In 2031 |
USD 32.49 Bn |
|
Growth Rate CAGR |
CAGR of 8.20% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application, Therapeutic Payload and End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Moderna Inc., Pfizer Inc., BioNTech SE, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., CureVac N.V., Lipocalyx, Acuitas Therapeutics, Precision NanoSystems Inc., IONTAS Limited, Genevant Sciences, Roche Holding AG, Alnylam Pharmaceuticals Inc., SiO2 Materials Science, Ethris GmbH, BIOVECTRA, Avanti Polar Lipids, Inc. (Croda International Plc.), Recipharm AB, eTheRNA, ST Pharm Co Ltd, and Other market players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
